Micro Rap is developing a diagnostic kit for type-1 diabetes and Biogen is developing a diagnostic kit for women with a genetic disposition for breast cancer.
Micromedic Technologies Ltd. (TASE:MCTC) portfolio companies Micro Rap Ltd. and Biogen Ltd. have obtained NIS 850,000 from the Office of the Chief Scientist to help finance their development programs at a cost of NIS 1.7 million.
Micro Rap is developing a diagnostic kit for type-1 diabetes (juvenile diabetes and latent autoimmune diabetes in adults (LADA)), based on RadioImmunoAssay technologies. Biogen is developing a diagnostic kit for women with a genetic disposition for breast cancer.
Published by Globes [online], Israel business news - www.globes-online.com - on June 7, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009